Celebrities are able to promote prescription drugs on social media without any required mention of potential side effects due to a legal loophole.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

Investigation finds 'influencer' dietitians paid to promote sugar, supplements on social media

A joint investigation by The Examiner and The Washington Post found that food, beverage, and supplement corporations and groups have paid registered dietitians on social media to promote content that goes against decades of scientific evidence on...

Deepfake videos impersonating real doctors are spreading false medical advice

More than 100 videos, found primarily on Instagram and TikTok in August 2025, promoted products related to beauty, wellness and weight loss. While TikTok removed 94% of content violating its policies on AI-generated content, these deepfakes were watched and shared before removal, undermining public trust in medicine.

Not everyone who is a candidate for GLP-1 is choosing to use the drug

One person writes about why, although she's a good fit for the medication on paper, she's decided not to take GLP-1 due to concerns about mental health and other side effects, among other reasons.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

Insurance coverage for GLP-1s remains uneven, but Medicare began covering it in some instances in July 2026.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

Medicare in early 2026 did not pay for GLP-1 for obesity treatment, and coverage under Medicaid varied widely by state.

Some influencers are facing the dark side of being a public persona

From burnout to stalkers, a content creator’s life can quickly become complicated as their following grows. Women’s Health recently spoke with some creators about what they wish they’d known before they started their careers on social media.

Social media platforms benefit not just from ensuring they have satisfied users, but also from the personal data they scoop up and can then sell to online advertisers.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for).

Social media addiction, though not a clinical diagnosis, refers to the idea that infinite scroll, notifications, and algorithms override one's ability to stop using them.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

Weight Watchers began offering access to GLP-1 weight-loss medications in 2023 after losing more than 1.5 million members over the previous two years.

Talk show host Oprah Winfrey spent about $43M in 2015 to buy a 10% stake in Weight Watchers and join its board of directors, going on to lose 40lbs using the program.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

How semaglutides are both better and worse than we know

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.

The popularity of new weight loss drugs has led to a diabetes treatment shortage

The FDA approved Ozempic to help patients with diabetes, but the popularity of semaglutide as a weight loss drug led doctors to prescribe Ozempic to nondiabetic patients who needed to lose weight. Ozempic became so popular that manufacturers could not keep pace with demand, posing risks for Ozempic-users with diabetes.

Top creators get paid millions of dollars per post

From the Kardashians to the world’s top soccer players, a handful of celebrities average hundreds of thousands, if not millions of dollars, per sponsored post. But brands aren’t willing to shell out that money for a high follower count alone. Creators must have high engagement rates on their content, too.

A major dopamine hit from social media use comes from unpredictability—not knowing if the content users post or share will get the 'like' from other users, triggering cycles of anticipation similar to those experienced with a slot machine.

Supplement sales soared during the pandemic, alongside growing distrust of the health establishment, amplifying a trend that endures—even when some of the products don't even work.

At-home genetic testing results commonly led users to healthier lifestyles

Italian research that aimed to investigate what people do longer-term after receiving direct-to-consumer genetic test results indicated that whether the results were positive or negative, people tended to adopt a healthier diet after receiving the results, and they'd still maintained it a year after receiving their results. Some users also reported an overall reduction in stress over their health concerns. (Some users may encounter a paywall.)

Fame can trigger addictive, drug-like highs in the brain

Differences in the type of fame, such as movie stardom, sports, and internet virality, can produce varying degrees of dependence on individuals based on their age and background. Some individuals—particularly children—can develop drug-seeking behavior as they pursue continuous dopamine spikes if they lack an existing sense of fulfillment from elsewhere.

The US FDA issued a 2025 warning about BPC-157 and other popular peptides that are marketed for various regenerative properties.

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.